Rutgers Study Finds GLP-1 Drugs Weaken Violence Link by 62% in Current Users
Updated
Updated · Gizmodo · Jun 17
Rutgers Study Finds GLP-1 Drugs Weaken Violence Link by 62% in Current Users
3 articles · Updated · Gizmodo · Jun 17
Summary
7,521 U.S. adults in a national survey showed current GLP-1 users had a far weaker tie between impulsivity and violent behavior than former users, according to a Rutgers study published in Criminology.
Current users showed a 62% weaker impulsivity-violence link and a 52% weaker alcohol-violence link, though the alcohol finding became less clear after additional analysis.
821 respondents had ever used a GLP-1 and 597 were current users; researchers compared those groups after earlier work suggested the drugs can alter craving, reward processing and impulse control.
Rutgers said the cross-sectional observational study does not prove GLP-1 drugs reduce violence or prevent crime, and called for longitudinal data to test causality as use of the medicines expands.
Can a drug curb violent impulses while offering no broad mental health benefits and increasing overall medical costs?
Beyond reducing cravings, could altering the brain's reward system also diminish our capacity for joy and motivation?
GLP-1s and Violence: Rutgers 2025 Data Reveal Surprising Behavioral Benefits Beyond Weight Loss
Overview
A recent Rutgers University study analyzed data from over 7,500 U.S. adults and found that people using GLP-1 receptor agonists, such as Ozempic and Wegovy, showed a weaker link between impulsivity and violent behavior. While these drugs are best known for treating diabetes and obesity by improving blood sugar control and reducing appetite, the research suggests they may also help reduce aggression. However, because the study was observational and cross-sectional, it cannot prove that GLP-1 medications directly cause these behavioral changes. The findings highlight the need for further research to understand how these drugs might influence complex behaviors.